Title |
Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine
|
---|---|
Published in |
Frontiers in oncology, March 2017
|
DOI | 10.3389/fonc.2017.00050 |
Pubmed ID | |
Authors |
Sara Victoria Soldera, Natasha B. Leighl |
Abstract |
Despite advances in molecular characterization and lung cancer treatment in recent years, treatment options for patients diagnosed with squamous cell carcinoma of the lung (SCC) remain limited as actionable mutations are rarely detected in this subtype. This article reviews potential molecular targets and associated novel agents for the treatment of advanced SCC in the era of personalized medicine. Elements of various pathways including epidermal growth factor receptor, PI3KCA, fibroblast growth factor receptor, retinoblastoma, cyclin-dependent kinases, discoidin domain receptor tyrosine kinase 2, and mesenchymal-to-epithelial transition may play pivotal roles in the development of SCC and are under investigation for drug development. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 48 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 15% |
Researcher | 7 | 15% |
Student > Doctoral Student | 5 | 10% |
Student > Bachelor | 4 | 8% |
Student > Master | 4 | 8% |
Other | 8 | 17% |
Unknown | 13 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 38% |
Biochemistry, Genetics and Molecular Biology | 7 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
Agricultural and Biological Sciences | 3 | 6% |
Immunology and Microbiology | 2 | 4% |
Other | 3 | 6% |
Unknown | 11 | 23% |